PRA Health Sciences (PRAH) : Traders are bullish on PRA Health Sciences (PRAH) as it has outperformed the S&P 500 by a wide margin of 8.36% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.95%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.88% in the last 1 week, and is up 12% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 7.57% and the 50-Day Moving Average is 4.77%. PRA Health Sciences, Inc. has dropped 2.26% during the last 3-month period . Year-to-Date the stock performance stands at 2.45%.
PRA Health Sciences (NASDAQ:PRAH): stock turned positive on Friday. Though the stock opened at $45.22, the bulls momentum made the stock top out at $47.24 level for the day. The stock recorded a low of $43.41 and closed the trading day at $46.38, in the green by 5.70%. The total traded volume for the day was 2,233,187. The stock had closed at $43.88 in the previous days trading.
Also, Credit Suisse initiates coverage on PRA Health Sciences (NASDAQ:PRAH) The current rating of the shares is Neutral. Equity Analysts at the Firm announces the price target to $43 per share. The rating by the firm was issued on June 21, 2016.
PRA Health Sciences, Inc. is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. The Company performs an array of services across the spectrum of clinical development programs, from the filing of investigational new drug (INDs) and similar regulatory applications to conducting all phases of clinical trials. Its service offerings include Product Registration Services, which includes Phase IIb through III product registration trials and Phase IV trials, inclusive of post-marketing commitments and registries; Strategic Solutions, which provides Embedded Solutions and functional outsourcing services, and Early Development Services, which includes Phase I through Phase IIa clinical trials and bioanalytical laboratory services.